Key result
Eplerenone reduced reactive fibrosis in the viable myocardium at 28 days post-MI compared with vehicle-treated rats, without retarding infarct healing or reparative collagen deposition.
Why the study?
Does eplerenone improve infarct healing and left ventricular remodeling in Sprague-Dawley rats post-myocardial infarction?
Population
Sprague-Dawley rats with induced myocardial infarction
Comparison
Eplerenone vs Vehicle
Design
Preclinical
Follow-up
28 days
Authors
Loading...
Supports targeted post-MI fibrosis modulation in rats; leaves open translation to human remodeling outcomes.
Does eplerenone improve infarct healing and left ventricular remodeling in Sprague-Dawley rats post-myocardial infarction?
Eplerenone protects against maladaptive reactive fibrosis after myocardial infarction in a rat model without impairing necessary infarct healing.
Delyani et al. (2001) studied Myocardial infarction. Eplerenone vs. Vehicle was evaluated on Infarct healing and left ventricular remodeling (diastolic pressure-volume relationship, infarct-thinning ratio, and collagen-volume fraction). Eplerenone reduced reactive fibrosis in the viable myocardium at 28 days post-MI compared with vehicle-treated rats, without retarding infarct healing or reparative collagen deposition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: